Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
Harvard Business School
AstraZeneca
Merck

Last Updated: September 26, 2022

LANIAZID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Laniazid patents expire, and what generic alternatives are available?

Laniazid is a drug marketed by Lannett and is included in three NDAs.

The generic ingredient in LANIAZID is isoniazid. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isoniazid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Laniazid

A generic version of LANIAZID was approved as isoniazid by MIKART on June 26th, 1997.

  Sign up for a Free Trial

US Patents and Regulatory Information for LANIAZID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett LANIAZID isoniazid SYRUP;ORAL 089243-001 Feb 3, 1986 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lannett LANIAZID isoniazid TABLET;ORAL 089776-001 Jun 13, 1988 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lannett LANIAZID isoniazid TABLET;ORAL 080140-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lannett LANIAZID isoniazid TABLET;ORAL 080140-002 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.